{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"562","value":"1800"},{"groupId":"OG001","spread":"1700","value":"4510"},{"groupId":"OG002","spread":"1140","value":"5970"},{"groupId":"OG003","spread":"3180","value":"5300"},{"groupId":"OG004","spread":"1020","value":"5780"},{"groupId":"OG005","spread":"4660","value":"9800"},{"groupId":"OG006","spread":"2670","value":"9500"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib 300 mg (Fasted): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG001","title":"Alectinib 460 mg (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG002","title":"Alectinib 600 mg (Fed): Phase I (20/40 mg)"},{"description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG003","title":"Alectinib 600 mg (Fed): Phase I (150 mg)"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG004","title":"Alectinib 760 mg (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG005","title":"Alectinib 900 mg (Fed): Phase I (20/40 mg)"},{"description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG006","title":"Alectinib 900 mg (Fed): Phase I (150 mg)"}],"paramType":"MEAN","populationDescription":"Phase I PK evaluable population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8 and 10 hours post-dose on Cycle 2 Day 1 (1 cycle = 21 days)","title":"AUC From Time Zero to Last Measurable Concentration (AUClast) After Multiple Dose of Alectinib: Phase I","type":"SECONDARY","unitOfMeasure":"hour*ng/mL"}